As of 26 May 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of the following health technologies for possible government financing:

• HIV Self Test Kit for screening of HIV infection in adults belonging to HIV and sexually transmitted infection key populations
• HIV/Syphilis Duo Test for screening of HIV and Syphilis infection in pregnant women as part of antenatal care, ideally during the first trimester
• In Vitro Quantitative HIV Nucleic Acid Test (HIV-NAT 1) for screening and diagnosis of HIV type 1 (HIV-1) infection in HIV-exposed infants and children
• Silver Diamine Fluoride 38% Clear Topical Solution for prevention and arrest of dentine caries in primary and permanent teeth among children 12 months to 10 years old

These health technologies were reviewed against clinical practice guidelines (CPGs) [local and approved by the DOH, such as the DOH Omnibus Health Guidelines (OHG); and/or international, but locally adopted guidelines], and existing recommendations by the World Health Organization (WHO). Further, costing analyses of these health technologies were performed. The specific recommendations and the supporting evidence reviewed and considered by the HTA Council are shown in Annex A.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 10 June 2025 (Tuesday), for the consideration of the HTA Council through email at hta@dost.gov.ph. 

Please use the prescribed form for appeals indicated on the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please do not hesitate to contact us through the same email address or via telephone call at (02) 8837-2071 local 4100.